New approaches for the treatment of Alzheimer's disease

被引:122
|
作者
Fish, Paul V. [1 ,2 ]
Steadman, David [1 ]
Bayle, Elliott D. [1 ,2 ]
Whiting, Paul [1 ,3 ]
机构
[1] UCL, Alzheimers Res UK UCL Drug Discovery Inst, Cruciform Bldg,Gower St, London WC1N 1E 6BT, England
[2] Francis Crick Inst, 1 Midland Rd, London NW1 1AT, England
[3] UCL, Dementia Res Inst, Cruciform Bldg,Gower St, London WC1N 1E 6BT, England
基金
英国医学研究理事会; 英国工程与自然科学研究理事会; 英国惠康基金;
关键词
Alzheimer's disease; Neurodegeneration; Neuroinflammation; Drug discovery pipeline; Symptomatic treatments; Disease modification; 5-HT6 RECEPTOR ANTAGONIST; DOUBLE-BLIND; AMYLOID HYPOTHESIS; CHOLINERGIC SYSTEM; TAU-AGGREGATION; MILD; EFFICACY; MODERATE; SAFETY; INHIBITOR;
D O I
10.1016/j.bmcl.2018.11.034
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alzheimer's disease (AD) is the most prevalent chronic neurodegenerative disease. Current approved therapies are symptomatic treatments having some effect on cognitive function. Therapies that target beta-amyloid (A beta) have been the focus of efforts to develop a disease modification treatment for AD but these approaches have failed to show any clinical benefit so far. Beyond the 'A beta hypothesis', there are a number of newer approaches to treat AD with neuroinflammation emerging as a very active area of research based on risk gene analysis. This short review will summarize approved drug therapies, recent clinical trials and new approaches for the treatment of AD.
引用
收藏
页码:125 / 133
页数:9
相关论文
共 50 条
  • [1] Advances in Alzheimer's disease's pharmacological treatment
    Conti Filho, Carlos Elias
    Loss, Lairane Bridi
    Marcolongo-Pereira, Clairton
    Rossoni Junior, Joamyr Victor
    Barcelos, Rafael Mazioli
    Chiarelli-Neto, Orlando
    Silva, Bruno Spalenza da
    Passamani Ambrosio, Roberta
    Castro, Fernanda Cristina de Abreu Quintela
    Teixeira, Sarah Fernandes
    Mezzomo, Nathana Jamille
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [2] Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease
    Van Bulck, Michiel
    Sierra-Magro, Ana
    Alarcon-Gil, Jesus
    Perez-Castillo, Ana
    Morales-Garcia, Jose A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (03)
  • [3] Treatment of Alzheimer's Disease and Future Approaches.
    Forette, Francoise
    Hauw, Jean-Jacques
    THERAPIE, 2010, 65 (05): : 429 - 437
  • [4] Current approaches to the pharmacological treatment of Alzheimer's disease
    Tan, Edwin C. K.
    Hilmer, Sarah N.
    Garcia-Ptacek, Sara
    Bell, J. Simon
    AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2018, 47 (09) : 586 - 592
  • [5] Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease
    Ruthirakuhan, Myuri
    Herrmann, Nathan
    Suridjan, Ivonne
    Abraham, Eleenor H.
    Farber, Ilan
    Lanctot, Krista L.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (18) : 2417 - 2429
  • [6] Donepezil in the treatment of patients with Alzheimer's disease
    Tsuno, Norifumi
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (05) : 591 - 598
  • [7] Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer's Disease
    Rajput, Shivam
    Malviya, Rishabha
    Bahadur, Shiv
    Puri, Dinesh
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (35) : 2802 - 2813
  • [8] Pharmacologic treatment of depression in Alzheimer's disease
    Haussmann, Robert
    Donix, Markus
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2023, 38 (02) : 81 - 88
  • [9] Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions
    Amanatkar, Hamid Reza
    Grossberg, George Thomas
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (10) : 1119 - 1125
  • [10] Neuromodulation in the Treatment of Alzheimer's Disease: Current and Emerging Approaches
    Pople, Christopher B.
    Meng, Ying
    Li, Daniel Z.
    Bigioni, Luca
    Davidson, Benjamin
    Vecchio, Laura M.
    Hamani, Clement
    Rabin, Jennifer S.
    Lipsman, Nir
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 78 (04) : 1299 - 1313